サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726269

糖尿病網膜症の世界市場：市場規模・シェア・動向分析 (種類別・管理法別・地域別)、セグメント別予測 (2025年～2030年)

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative Diabetic Retinopathy), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
糖尿病網膜症の世界市場：市場規模・シェア・動向分析 (種類別・管理法別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年04月16日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病網膜症市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の糖尿病網膜症市場は2030年までに137億7,000万米ドルに達し、予測期間中にCAGR 6.4％で拡大すると予測されています。

複数の地域での糖尿病罹患率の上昇と、糖尿病網膜症（DR）の効率的な管理と効果的な治療の重要性に関する意識の高まりが、主要な市場促進要因です。糖尿病網膜症の治療が間に合わなければ、重度の視力障害や失明に至る可能性もあります。医療インフラが改善され、最新の治療法へのアクセスが向上していることが、市場の成長を促進すると予想されます。

複数の地域で糖尿病と診断される患者数が大幅に増加していることも、同市場の成長に寄与しています。また、早期発見と血糖値の効果的な管理の重要性に関する意識の高まりも、市場の成長を後押ししています。さらに、糖尿病に関連した失明症例の増加に関連する憂慮すべき統計も増加しており、この市場の成長を支えるものと期待されています。

米国糖尿病協会の報告によると、糖尿病患者は緑内障、白内障、黄斑浮腫などの眼疾患を発症するリスクがあります。米国疾病予防管理センターによると、米国では約3,840万人が糖尿病を患っています。

糖尿病網膜症市場：分析概要

  • 非増殖糖尿病網膜症が2024年に70.0％以上のシェアを占め、市場を独占します。
  • 予測期間中、レーザー手術が最も速いCAGRで成長する見込みです。
  • 抗VEGF管理分野は、2024年に92.3％の最大市場シェアを占めました。
  • 医療投資の増加と技術の進歩が市場成長に寄与しました。
  • 北米は、認知度の向上、洗練された医療インフラ、抗VEGF薬の高い市場浸透により、世界市場を独占しました。
  • 2024年9月、インドの国家規制当局は、紹介可能なDRの自動検出を容易にする眼科AIソフトウェアRemidio Medios DR AIを承認しました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 糖尿病網膜症市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 糖尿病網膜症市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 糖尿病網膜症市場：種類別の推定・動向分析

  • 種類別のダッシュボード
  • 糖尿病網膜症市場：種類別の変動分析
  • 世界の糖尿病網膜症市場：市場規模の予測と動向分析、種類別 (2018～2030年)
  • 増殖性糖尿病網膜症
  • 非増殖性糖尿病網膜症

第5章 糖尿病網膜症市場：管理法別の推定・動向分析

  • 管理法別のダッシュボード
  • 糖尿病網膜症市場：管理法別の変動分析
  • 世界の糖尿病網膜症市場：市場規模の予測と動向分析、管理法別 (2018～2030年)
  • 抗VEGF
  • 眼内ステロイド注射
  • レーザー手術
  • 硝子体切除術

第6章 糖尿病網膜症市場：地域別の推定・動向分析

  • 市場ダッシュボード：地域別
  • 市場シェア分析：地域別（2024年・2030年）
  • 連続バイオプロセス市場：主なポイント、地域別
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • タイ
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要企業のヒートマップ分析（2024年）
  • 企業プロファイル
    • Bayer AG
    • AbbVie Inc.
    • Novartis AG
    • Oxurion NV.
    • Sirnaomics, Inc.
    • Alimera Sciences
    • Ampio Pharmaceuticals Inc.
    • BCN Peptides
    • Kowa Company, Ltd.
    • Genentech, Inc.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 5 U.S. diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 7 Canada diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 9 Mexico diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 11 Europe diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 12 Europe diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 14 UK diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 15 UK diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 16 Germany diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 18 France diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 19 France diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 20 Italy diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 21 Italy diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 22 Spain diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 23 Spain diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 24 Denmark diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 25 Denmark diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 26 Sweden diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 27 Sweden diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 28 Norway diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 29 Norway diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 33 Japan diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 35 China diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 36 China diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 37 India diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 38 India diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 39 South Korea diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 40 South Korea diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 41 Thailand diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 43 Australia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 44 Australia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 45 Latin America diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 46 Latin America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 47 Latin America surgical ablation market, by management, 2018 - 2030 (USD Million)
  • Table 48 Brazil diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 49 Brazil diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 50 Argentina diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 51 Argentina diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 52 MEA diabetic retinopathy market, by country, 2018 - 2030 (USD Million)
  • Table 53 MEA diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 54 MEA diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 55 South Africa diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 56 South Africa diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 59 UAE diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 60 UAE diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
  • Table 61 Kuwait diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait diabetic retinopathy market, by management, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Diabetic retinopathy market: market outlook
  • Fig. 10 Diabetic retinopathy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Diabetic retinopathy market driver impact
  • Fig. 16 Diabetic retinopathy market restraint impact
  • Fig. 17 Diabetic retinopathy market strategic initiatives analysis
  • Fig. 18 Diabetic retinopathy market: Type movement analysis
  • Fig. 19 Diabetic retinopathy market: Type outlook and key takeaways
  • Fig. 20 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
  • Fig. 21 Non-proliferative diabetic retinopathy estimates and forecast, 2018 - 2030
  • Fig. 22 Diabetic retinopathy market: Management movement analysis
  • Fig. 23 Diabetic retinopathy market: Management outlook and key takeaways
  • Fig. 24 Anti-VEGF market estimates and forecasts, 2018 - 2030
  • Fig. 25 Intraocular steroid injection market estimates and forecasts,2018 - 2030
  • Fig. 26 Laser surgery market estimates and forecasts, 2018 - 2030
  • Fig. 27 Vitrectomy market estimates and forecasts, 2018 - 2030
  • Fig. 28 Global diabetic retinopathy market: regional movement analysis
  • Fig. 29 Global diabetic retinopathy market: regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 37 France market estimates and forecasts, 2018 - 2030
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 40 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 45 China market estimates and forecasts, 2018 - 2030
  • Fig. 46 India market estimates and forecasts, 2018 - 2030
  • Fig. 47 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 49 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 54 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: 978-1-68038-466-6

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market is anticipated to reach USD 13.77 billion by 2030 and expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

Diabetic Retinopathy Market Report Highlights:

  • Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.
  • Laser surgery is expected to grow at the fastest CAGR over the forecast period.
  • The anti-VEGF management segment held the largest market share of 92.3% in 2024.
  • The rise in healthcare investments and advancements in technology contribute to market growth.
  • North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.
  • In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Management
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Management Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Diabetic Retinopathy Market Analysis tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Diabetic Retinopathy Market: Type Movement Analysis
  • 4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Proliferative Diabetic Retinopathy
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-Proliferative Diabetic Retinopathy
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

  • 5.1. Management Segment Dashboard
  • 5.2. Diabetic Retinopathy Market: Management Movement Analysis
  • 5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
  • 5.4. Anti-VEGF
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Intraocular Steroid Injection
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Laser Surgery
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Vitrectomy
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.1.3. Competitive Scenario
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.1.3. Competitive Scenario
      • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.6.3. Competitive Scenario
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.7.3. Competitive Scenario
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.8.3. Competitive Scenario
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.1.3. Competitive Scenario
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Argentina
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.3.3. Competitive Scenario
      • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.4.3. Competitive Scenario
      • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Bayer AG
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. AbbVie Inc.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Oxurion NV.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Sirnaomics, Inc.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Alimera Sciences
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Ampio Pharmaceuticals Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. BCN Peptides
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Kowa Company, Ltd.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Genentech, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives